After examining the impact of the 2017 Amendment, we submitted a request to receive a tax ruling from the Israel Tax Authority to be recognized as a Preferred Technology Enterprise and recently we received a tax ruling from the Israel Tax Authority granting GRD a Preferred Technology Enterprise status, subject to terms and conditions determined in the tax ruling.

        The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.

Nanayakkara, P. W. et al. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation 53, 41–50, doi:10.1053/j.ajkd.2008.06.016 (2009).

The cytolytic activity of NK cells requires an initial Ca2+ influx for conjugation with the tumor cells, and intracellular Ca2+ mobilization is required for granule polarization and the degranulation process7. However, the activation processes that lead to the polarized degranulation of NK cells are not well understood. We have demonstrated here that cytolytic granule exocytosis and the antitumor functions of NK cells rely upon signaling pathways involving CD38, ADPR, and TRPM2, and Ca2+ release from acidic stores. The inhibition of this signaling pathway significantly decreased the cytolytic granule exocytosis and antitumor activity in both in vitro and in vivo models.

Bachem supplies peptides and organic active ingredients whose patent protection has lapsed. This business segment accounts for 30% of Bachem’s sales revenue.

        While we have not filed for protection in the U.S. or abroad for our mark, EXTREME DIVERSITY, we do use the mark and rely on common law protections for such use for goods and services.

Our employees, principal investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards.

The same scientists also developed a continuous flow process for the selective nitration of 1-methyl-4-(methylsulfonyl)benzene in 98% yield using 80 weight percent (wt%) sulfuric acid (3). The short residence time of 5 s led to a significant reduction in byproduct formation. Notably, the spent acid could be reused multiple times after concentration under a vacuum.

Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and future product candidates and the methods used to develop and manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our products depends on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We believe that our patents provide broad and comprehensive coverage for the use of Aramchol for the treatment of certain liver diseases and other metabolic diseases. However, the patent positions of biopharmaceutical companies, such as ourselves, are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for the technology will depend on our success in obtaining effective claims and enforcing those claims once granted. There is no certainty that any of the Company’s pending patent applications will result in the issuance of any patents. The issued patents and those that may be issued in the future, may be challenged, narrowed, circumvented or found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length of term of patent protection that we may have for our products. In addition, our competitors may independently develop similar technologies or duplicate any technology developed by us, and the rights granted under any issued or future patents may not provide us with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing and regulatory review of a potential product, before any of our products can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of such patent. For more risks associated with the protection of our licensed intellectual property, see “Item 3. Key Information—Risk Factors—Risks Related to Our Intellectual Property.” 

Korea, New Zealand, Russia, South Africa, and Taiwan. These patents are generally expected to expire between 2018 and 2022, subject to possible patent term extensions. We paid an aggregate amount of approximately $1.4 million and approximately 123,456 shares of common stock in connection with the Cosmix acquisition that includes this fully paid-up license, though no breakdown of amounts specifically attributable to this license is available.

atleast supplementation with nad+ increasing compounds should not be taking at the same time as rapamycin, and i am really considering if a weekly dose of rapamycin is the best approach, i would consider longer time in between.

Bachem has announced that the company has concluded an agreement with Atheris Laboratories to market their Melusine® libraries, consisting of natural products isolated from animal venoms. The agreement includes services to assist customers with the identification of the active ingredients a